Atsena Therapeutics: Funding, Investors & Team (Oct 2026)
Atsena Therapeutics is a company in the advanced stages of testing genetic therapy that aims to reverse or stop vision loss. They are currently conducting a clinical trial for a potential treatment targeting a common cause of childhood blindness. Atsena's research and development pipeline utilizes adeno-associated virus technology, which is designed to address the challenges associated with inherited retinal diseases. The company's approach is individualized to meet the unique requirements of each patient's condition.
Atsena Therapeutics has raised $175M across 2 funding rounds on record, the most recent a Series C of $150M announced in Apr 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Atsena Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2025.
Atsena Therapeutics Funding Rounds
Atsena Therapeutics raised $24.5M in an undisclosed round announced in Oct 2023.
1.5 years later, a Series C of $150M was announced in Apr 2025.
Atsena Therapeutics Founders and Leadership Team
Contact details for the Atsena Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Atsena Therapeutics Funding Compared to Other Biotechnology Startups
Atsena Therapeutics' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Atsena Therapeutics in Biotechnology and Durham
Companies Similar to Atsena Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Atsena Therapeutics Funding FAQs
What does Atsena Therapeutics do?
Atsena Therapeutics is a company in the advanced stages of testing genetic therapy that aims to reverse or stop vision loss. They are currently conducting a clinical trial for a potential treatment targeting a common cause of childhood blindness. Atsena's research and development pipeline utilizes adeno-associated virus technology, which is designed to address the challenges associated with inherited retinal diseases. The company's approach is individualized to meet the unique requirements of each patient's condition.
How much funding has Atsena Therapeutics raised?
Atsena Therapeutics has raised $175M across 2 rounds on record. The most recent is a Series C of $150M announced in Apr 2025.
When did Atsena Therapeutics last raise funding?
Atsena Therapeutics' most recent funding round on record is a Series C of $150M, announced in Apr 2025.
Who founded Atsena Therapeutics?
FundedIQ lists Sanford Boye (Founder), Shannon Boye (Founder) at Atsena Therapeutics.
Where is Atsena Therapeutics headquartered?
Atsena Therapeutics is based in Durham, North Carolina, United States.
How many employees does Atsena Therapeutics have?
Atsena Therapeutics is in the 11-50 employee band.
How does Atsena Therapeutics' funding compare to other Biotechnology startups?
Atsena Therapeutics' latest round of $150M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Atsena Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Atsena Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.